| James S Magera Jr, MD | |
|
2529 Glenn Hendren Dr Ste 202, Liberty, MO 64068-9602 | |
| (816) 781-8400 | |
| (816) 781-8263 |
| Full Name | James S Magera Jr |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 2529 Glenn Hendren Dr Ste 202, Liberty, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316927544 | NPI | - | NPPES |
| 327108100 | Medicaid | MN | |
| 43625029 | Other | BCBS KC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2010006699 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Liberty Hospital District | Liberty, MO | Hospital |
| North Kansas City Hospital | North kansas city, MO | Hospital |
| Saint Lukes North Hospital | Kansas city, MO | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Hedrick Medical Center | Chillicothe, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas City Urology Care Pa | 9032006853 | 61 |
| Kansas City Urology Care Pa | 9032006853 | 61 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.
A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.
CQ HealthBeat reports that insurers, hospitals and trade groups are offering only "limited interest" in the campaign to educate Americans about the health law's coverage expansion. Meanwhile, other supporters are backing the grassroots effort to keep the Obama administration's agenda - including the Medicaid expansion - on track.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.
EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
› Verified 1 days ago
| Entity Name | Excelsior Springs City Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285733923 PECOS PAC ID: 7315847209 Enrollment ID: O20040108000958 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.
A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.
CQ HealthBeat reports that insurers, hospitals and trade groups are offering only "limited interest" in the campaign to educate Americans about the health law's coverage expansion. Meanwhile, other supporters are backing the grassroots effort to keep the Obama administration's agenda - including the Medicaid expansion - on track.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.
EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
› Verified 1 days ago
| Entity Name | Ray County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245220052 PECOS PAC ID: 4688560634 Enrollment ID: O20040225001164 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.
A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.
CQ HealthBeat reports that insurers, hospitals and trade groups are offering only "limited interest" in the campaign to educate Americans about the health law's coverage expansion. Meanwhile, other supporters are backing the grassroots effort to keep the Obama administration's agenda - including the Medicaid expansion - on track.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.
EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
› Verified 1 days ago
| Entity Name | Kansas City Urology Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528024676 PECOS PAC ID: 9032006853 Enrollment ID: O20040304000362 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.
A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.
CQ HealthBeat reports that insurers, hospitals and trade groups are offering only "limited interest" in the campaign to educate Americans about the health law's coverage expansion. Meanwhile, other supporters are backing the grassroots effort to keep the Obama administration's agenda - including the Medicaid expansion - on track.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.
EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James S Magera Jr, MD 2529 Glenn Hendren Dr, Liberty, MO 64068-9607 Ph: (816) 781-8400 | James S Magera Jr, MD 2529 Glenn Hendren Dr Ste 202, Liberty, MO 64068-9602 Ph: (816) 781-8400 |
News Archive
Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.
A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.
CQ HealthBeat reports that insurers, hospitals and trade groups are offering only "limited interest" in the campaign to educate Americans about the health law's coverage expansion. Meanwhile, other supporters are backing the grassroots effort to keep the Obama administration's agenda - including the Medicaid expansion - on track.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company's Phase II-B clinical trial.
EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).
› Verified 1 days ago
Dr. Lauren Marie Compton, DNP, FNP-C, APRN Urology Medicare: Medicare Enrolled Practice Location: 2529 Glenn Hendren Dr Ste 202, Liberty, MO 64068 Phone: 816-781-8400 | |
Dr. Kenneth Patrick Collins, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2529 Glenn Hendren Dr Ste 202, Liberty, MO 64068 Phone: 816-781-8400 Fax: 816-781-8263 |